PRA Health Sciences (PRAH) Tops Q3 EPS by 7c; Lifts FY15 EPS Outlook

PRA Health Sciences (NASDAQ: PRAH) reported Q3 EPS of $0.52, $0.07 better than the analyst estimate of $0.45. Revenue for the quarter came in at $345.1 million versus the consensus estimate of $346.05 million.

PRA Health Sciences sees FY2015 EPS of $1.89-$1.92, versus prior guidance of $1.75-$1.85 and the consensus of $1.81.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance